Market Closed -
Nasdaq
21:30:00 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
2.39
USD
|
-2.05%
|
|
+1.70%
|
-52.20%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
590.5
|
351.1
|
423
|
145.7
|
415.5
|
203.1
|
-
|
-
|
Enterprise Value (EV)
1 |
590.5
|
351.1
|
423
|
145.7
|
415.5
|
156.4
|
202.7
|
280.8
|
P/E ratio
|
12.9
x
|
-5.32
x
|
-4.65
x
|
-2.22
x
|
-6.57
x
|
-3.28
x
|
-10.2
x
|
-8.97
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.32
x
|
22.8
x
|
-
|
37
x
|
28.1
x
|
24.4
x
|
3.32
x
|
3.07
x
|
EV / Revenue
|
5.32
x
|
22.8
x
|
-
|
37
x
|
28.1
x
|
18.8
x
|
3.32
x
|
4.24
x
|
EV / EBITDA
|
12.9
x
|
-5.92
x
|
-5.52
x
|
-2.13
x
|
-8.08
x
|
-2.16
x
|
-4.01
x
|
-3.55
x
|
EV / FCF
|
-
|
-5.73
x
|
-6.19
x
|
-1.95
x
|
-6.79
x
|
-2.38
x
|
6.74
x
|
5.02
x
|
FCF Yield
|
-
|
-17.4%
|
-16.2%
|
-51.3%
|
-14.7%
|
-42%
|
14.8%
|
19.9%
|
Price to Book
|
2.17
x
|
1.53
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
71,662
|
76,741
|
93,691
|
77,257
|
98,801
|
93,954
|
-
|
-
|
Reference price
2 |
8.240
|
4.575
|
4.515
|
1.886
|
4.205
|
2.162
|
2.162
|
2.162
|
Announcement Date
|
30/03/20
|
23/03/21
|
22/03/22
|
16/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
111
|
15.43
|
-
|
3.935
|
14.8
|
8.325
|
61.1
|
66.17
|
EBITDA
1 |
45.81
|
-59.29
|
-76.6
|
-68.49
|
-51.41
|
-72.5
|
-50.5
|
-79.1
|
EBIT
1 |
44.54
|
-61.26
|
-79.01
|
-70.85
|
-53.62
|
-67.84
|
-5.359
|
-4.026
|
Operating Margin
|
40.11%
|
-396.99%
|
-
|
-1,800.43%
|
-362.3%
|
-814.83%
|
-8.77%
|
-6.08%
|
Earnings before Tax (EBT)
1 |
45.44
|
-61.92
|
-72.99
|
-70.74
|
-54.22
|
-67.61
|
-5.259
|
-5.976
|
Net income
1 |
45.44
|
-61.92
|
-73
|
-70.75
|
-54.23
|
-66.6
|
-23.83
|
-26.75
|
Net margin
|
40.93%
|
-401.28%
|
-
|
-1,798.04%
|
-366.41%
|
-799.94%
|
-39%
|
-40.42%
|
EPS
2 |
0.6400
|
-0.8600
|
-0.9700
|
-0.8500
|
-0.6400
|
-0.6590
|
-0.2127
|
-0.2410
|
Free Cash Flow
1 |
-
|
-61.22
|
-68.32
|
-74.81
|
-61.21
|
-65.71
|
30.1
|
55.92
|
FCF margin
|
-
|
-396.75%
|
-
|
-1,901.07%
|
-413.55%
|
-789.27%
|
49.25%
|
84.52%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
23/03/21
|
22/03/22
|
16/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
3.934
|
0.001
|
-
|
-
|
-
|
14.8
|
5.325
|
0.5
|
0.5
|
3.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.28
|
-22.79
|
-18.83
|
-19.86
|
-13.46
|
-18.7
|
-17.57
|
-17.05
|
-15.47
|
-3.541
|
-10.79
|
-18.52
|
-18.84
|
-18.98
|
Operating Margin
|
-
|
-
|
-
|
-
|
-342.22%
|
-1,869,500%
|
-
|
-
|
-
|
-23.92%
|
-202.68%
|
-3,703.95%
|
-3,768.1%
|
-542.43%
|
Earnings before Tax (EBT)
1 |
-15.92
|
-21.27
|
-18.84
|
-19.64
|
-13.51
|
-18.74
|
-17.51
|
-16.83
|
-15.14
|
-4.743
|
-11.04
|
-18.34
|
-18.67
|
-18.86
|
Net income
1 |
-15.92
|
-21.28
|
-18.85
|
-19.64
|
-13.52
|
-18.75
|
-17.51
|
-16.83
|
-15.14
|
-4.744
|
-13.09
|
-18.13
|
-18.41
|
-16.57
|
Net margin
|
-
|
-
|
-
|
-
|
-343.57%
|
-1,874,600%
|
-
|
-
|
-
|
-32.05%
|
-245.82%
|
-3,625.61%
|
-3,681.71%
|
-473.47%
|
EPS
2 |
-0.2200
|
-0.2600
|
-0.2300
|
-0.2300
|
-0.1600
|
-0.2300
|
-0.2100
|
-0.2000
|
-0.1800
|
-0.0500
|
-0.1350
|
-0.1943
|
-0.1857
|
-0.1773
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/11/21
|
22/03/22
|
28/04/22
|
28/07/22
|
28/10/22
|
16/03/23
|
28/04/23
|
04/08/23
|
03/11/23
|
14/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
77.7
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
46.7
|
0.4
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.9823
x
|
Free Cash Flow
1 |
-
|
-61.2
|
-68.3
|
-74.8
|
-61.2
|
-65.7
|
30.1
|
55.9
|
ROE (net income / shareholders' equity)
|
20.2%
|
-25.4%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
3.790
|
3.000
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.89
|
1.71
|
2.64
|
1.24
|
0.8
|
1.34
|
1.55
|
1.62
|
Capex / Sales
|
1.7%
|
11.06%
|
-
|
31.49%
|
5.41%
|
16.05%
|
2.54%
|
2.45%
|
Announcement Date
|
30/03/20
|
23/03/21
|
22/03/22
|
16/03/23
|
14/03/24
|
-
|
-
|
-
|
Last Close Price
2.162
CHF Average target price
9.424
CHF Spread / Average Target +335.85% Consensus |
1st Jan change
|
Capi.
|
---|
| -52.20% | 225M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|